Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Get Quote
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbCellera Biologics Inc. - Common Shares
(NQ:
ABCL
)
4.240
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbCellera Biologics Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
3 Biotech Stocks Under $10 to Add to Your Buy List
April 26, 2022
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.
Via
InvestorPlace
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
April 12, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
April 08, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Sunday Memo - Dec. 5
December 05, 2021
The market rout was worldwide last week.
Via
Talk Markets
AbCellera Reports Full Year 2021 Business Results
February 24, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
February 23, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
February 14, 2022
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized...
Via
Benzinga
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
February 11, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
February 11, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
February 10, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
January 27, 2022
From
AbCellera
Via
Business Wire
Top Biotech Stocks: Trading Opportunities For Next Week
December 19, 2021
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns.
Via
Talk Markets
AbCellera Announces Changes to Its Board of Directors
December 07, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
Futures Rebound From Friday Rout As Omicron Fears Ease
December 06, 2021
S&P futures and European stocks rebounded from Friday’s selloff while Asian shares fell, as investors took comfort in reports from South Africa which said initial data doesn’t show a surge of...
Via
Talk Markets
Topics
Stocks
Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns
December 06, 2021
The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) bamlanivimab and etesevimab administered together to include...
Via
Benzinga
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
December 03, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
December 02, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
November 29, 2021
Smaller companies are working on next-generation approaches to Covid treatment.
Via
Investor's Business Daily
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
November 29, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Friday Markets Coverage
November 19, 2021
Today markets are suffering alongside Austria which locked down against Covid-19 again.
Via
Talk Markets
AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript
November 10, 2021
ABCL earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
AbCellera Reports Q3 2021 Business Results
November 09, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed
November 09, 2021
Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
AbCellera Announces Virtual Presentations at Investor Conferences in November
November 04, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
Why AbCellera Biologics Stock Sank 21.6% in October
November 04, 2021
The biotech is now down roughly 56% across 2021's trading.
Via
The Motley Fool
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
November 02, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.